← Back to Home

Reducing C. difficile Recurrence: Oral Biologic LMN-201 Shows Preliminary Results in a Small Phase 2 Trial

A combination protein drug produced using engineered spirulina increased the proportion of patients achieving sustained cure when added to antibiotics. But the randomized comparison included only 23 people, and the magnitude of efficacy and safety still need confirmation in larger trials.

By SURL BioNews

For patients with C. difficile infection, completing a course of antibiotics does not necessarily mean the illness is over; recurrence can lead to another round of treatment and hospitalization. Phase 2 trial results announced by Lumen Bioscience offer preliminary clues toward breaking this cycle: a higher proportion of patients achieved initial treatment success without recurrence when the oral biologic LMN-201 was added to standard antibiotics than when placebo was added. However, this difference came from a randomized comparison involving only 23 people.

The study, called RePreve, enrolled 45 people in total, but its main randomized, double-blind comparison came from Part B. Participants were assigned to groups with stratification by antibiotic type and age. Both groups received oral vancomycin or fidaxomicin, along with LMN-201 or placebo during and after antibiotic treatment. The trial therefore assessed whether adding the drug could improve outcomes with existing treatment; it has not yet answered whether the drug can treat the infection on its own.

The primary endpoint, “global cure,” combined initial treatment success with the absence of subsequent recurrence. In the LMN-201 group, 10 of 12 participants met this endpoint, compared with 4 of 11 in the placebo group: 83.3% and 36.4%, respectively, a difference of approximately 47 percentage points. Lumen said the results met the prespecified success criterion for the Bayesian statistical analysis, but the current announcement did not provide sufficient detail to independently assess statistical uncertainty.

Recurrence results also moved in a favorable direction, with the company reporting rates of 9.1% and 55.6% in the two groups, respectively. However, another secondary endpoint measuring initial treatment failure did not reach statistical significance. This distinction means that the improvement in global cure cannot be directly interpreted as establishing that the drug improves initial treatment success; the individual results still need to be interpreted within the complete follow-up data.

LMN-201 is designed to combine three toxin-binding proteins and one antibacterial enzyme in oral capsules. These components are produced using engineered spirulina, with the aim of addressing both toxins and bacteria. Spirulina thus serves as a drug manufacturing platform here; the available clinical data cannot yet distinguish how much each component contributes to efficacy.

On safety, Lumen said adverse event rates were similar between the two groups, with no drug-related serious adverse events or deaths reported. However, the small sample makes uncommon risks difficult to identify and limits both the precision of efficacy estimates and judgments about whether the results apply to a broader patient population. Reports by Contagion Live and Pharmacally also noted these limitations; the available information still comes primarily from the company announcement, and the associated paper is being prepared.

The next test is whether this early signal can be reproduced in larger studies. According to excerpts from a Scrip interview posted on Lumen’s website, the company is seeking a larger partner to advance LMN-201 into Phase 3 development and argues that the spirulina platform has the potential for scaled-up production. More RePreve data are scheduled to be presented at the IDWeek annual meeting on October 24; until the full analysis and subsequent validation are available, these results support continued research but are not yet sufficient to change routine treatment.

References

  1. Lumen Bioscience
  2. Contagion Live
  3. Lumen Bioscience (hosted Scrip excerpt)
  4. Pharmacally